WHILE it is understood that the individual pharmacist can not directly influence the Therapeutic Goods Administration S4 to S3 switch policy, individual strategies can be implemented to prepare for those products with a strong likelihood of approval for switch, says the World Self Medication Industry (WSMI).
The 2017 WSMI General Assembly will be held in Sydney 18-19 Oct with an emphasis on the switch strategy for driving future business.
Dr Hubertus Cranz, director general for the Association of the European Self-Medication Industry (AESGP) will be one of the key speakers at the event, along with Consumer Health Products Canadian president Karen Proud and Denise Hope from the School of Pharmacy and Pharmacology, Griffith University, Queensland.
Drugs of interest for switch strategies include those for erectile dysfunction, oral contraceptive pills, triptans for migraine and PPI's for GORD - CLICK HERE for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Sep 17
